Integrative bioinformatics and experimental validation unveil CRISP3 as a hypoxia-, epithelial mesenchymal transition-, and immune-related prognostic biomarker and therapeutic target in breast cancer
This study establishes a novel HEMTIRGs-based prognostic model for BC, offering a robust tool for predicting patient prognosis and immunotherapy efficacy. Additionally, our findings provide new insights into BC pathogenesis, highlighting potential therapeutic targets.
Authors
- Nan Cao (ORCID: https://orcid.org/0000-0003-1316-7515)
- Yue Cui (ORCID: https://orcid.org/0000-0003-1882-5441)
- Yaning Zhang (ORCID: https://orcid.org/0000-0001-5763-298X)
- Yahuan Guo
- Xu Li (ORCID: https://orcid.org/0000-0001-5221-0817)
- Zhen Wang (ORCID: https://orcid.org/0009-0008-5083-1853)
- Yi‐Rong Li
- Zeyu Xing (ORCID: https://orcid.org/0000-0002-8982-3892)
- Yuanyuan Ren (ORCID: https://orcid.org/0000-0002-6928-7105)
- Yi Yu (ORCID: https://orcid.org/0000-0003-1667-5187)
Institutions
- Ministry of Education of the People's Republic of China (CN)
- Shanxi Medical University (CN)
- Northwest University (CN)
- Shaanxi Provincial People's Hospital (CN)
- Shanxi Provincial People’s Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-22
- DOI
- https://doi.org/10.3389/fimmu.2025.1634399
- Citations
- 1
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.94